The Technical Analyst
Fusion Pharmaceuticals [FUSN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Fusion Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.09% $21.26
America/New_York / 16 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 800.56 mill |
| EPS: | -1.450 |
| P/E: | -14.66 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 84.69 mill |
| Avg Daily Volume: | 2.23 mill |
| RATING 2024-04-16 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.66 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.49x |
| Company: PE -14.66 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.831 (-103.91%) $-22.09 |
| Date: 2024-04-16 |
| Expected Trading Range (DAY) |
|---|
|
$ 20.13 - 22.37 ( +/- 5.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-04 | Leamon Christopher P | Buy | 106 100 | Stock Option (Right to Buy) |
| 2024-01-04 | Leamon Christopher P | Buy | 63 700 | Restricted Stock Units |
| 2023-08-31 | Leamon Christopher P | Buy | 11 957 | Common Stock |
| 2024-01-04 | Crowley John J | Buy | 106 100 | Stock Option (Right to Buy) |
| 2024-01-04 | Crowley John J | Buy | 63 700 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 99.95 |
| Last 91 transactions |
| Buy: 6 470 725 | Sell: 164 236 |
Forecast:
16:00 - $21.26
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $21.26
Forecast 2: 16:00 - $21.26
Forecast 3: 16:00 - $21.26
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $21.26 (-0.09% ) |
| Volume | 0.550 mill |
| Avg. Vol. | 2.23 mill |
| % of Avg. Vol | 24.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FUSN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $11.30 | N/A | Active |
|---|
FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Latest Press Releases
2024-04-09 16:05:00 - Press Release
Fusion Pharmaceuticals Announces Presentation Of Interim Data From The Phase 2 Tatcist Clinical Trial Evaluating Fpi-2265 At The Aacr Annual Meeting 2024
Preliminary data demonstrate fpi-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mcrpc), including those who received prior lutetium-based radioconjugates hamilton, on and boston , april 9, 2024 /prnewswire/ -- fusion pharmaceuticals inc. (nasdaq: fusn), a clinical-stage oncology company focused on developing next-generation radioconjugates (rcs) as precision medicines, today announced the presentation of interim efficacy and safety data from the phase 2 tatcist open-label clinical trial evaluating fpi-2265, at the american association for cancer research (aacr) annual meeting 2024 being held april 5-10 in san diego, california...
2024-03-26 19:48:00 - Press Release
Investigation: The M&a Class Action Firm Announces An Investigation Of Fusion Pharmaceuticals Inc. - Fusn
New york , march 26, 2024 /prnewswire/ -- monteverde & associates pc (the "m&a class action firm"), has recovered money for shareholders and is recognized as a top 50 firm in the 2018-2022 iss securities class action services report. we are headquartered at the empire state building in new york city and is investigating fusion pharmaceuticals inc. (nasdaq: fusn), relating to its proposed sale to astrazeneca.
2024-03-20 16:05:00 - Press Release
Fusion Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Announces Clinical Program Updates
Company recently announced definitive agreement to be acquired by astrazeneca fpi-2265 phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mcrpc) expected to begin in q2 2024 interim data from tatcist study of fpi-2265 to be presented at the 2024 american association for cancer research (aacr) annual meeting in april fusion is now producing and shipping clinical doses of fpi-2265 from its state-of-the-art gmp manufacturing facility hamilton, on and boston, march 20, 2024 /prnewswire/ -- fusion pharmaceuticals inc. (nasdaq: fusn), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided an update on clinical and corporate developments...
2024-03-19 21:01:00 - Press Release
Fusion Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Fusion Pharmaceuticals Inc. - Fusn
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of fusion pharmaceuticals inc. (nasdaqgs: fusn) to astrazeneca. under the terms of the proposed transaction, astrazeneca would acquire all of fusion's outstanding shares for $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement o.
2024-03-19 07:30:00 - Press Release
Fusn Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Fusion Pharmaceuticals Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of fusion pharmaceuticals inc. (nasdaq: fusn) to astrazeneca is fair to fusion shareholders. under the terms of the proposed transaction, astrazeneca would acquire all of fusion's outstanding shares for $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. halper sadeh.
Latest News
2024-04-11 18:56:09 - Zacks Investment Research
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
In the most recent trading session, Fusion Pharmaceuticals Inc. (FUSN) closed at $21.36, indicating no shift from the previous trading day.
2024-03-25 13:07:32 - Seeking Alpha
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
2024-03-20 14:25:19 - Zacks Investment Research
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
2024-03-19 08:51:53 - Proactive Investors
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting
AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail in targeted cancer treatment. Fusion specialises in the development of radioconjugates, which focuses on delivering radioactive isotopes directly to cancer cells through precise targeting mechanisms.
2024-03-19 03:45:00 - Market Watch
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
2024-03-05 16:43:00 - PRNewsWire
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
HAMILTON, ON and BOSTON , March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. Presentation at AACR Annual Meeting 2024: Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) Session: Phase II Clinical Trials 1 Session Date and Time: Tuesday April 9, 2024, 9:00 a...
2024-03-03 01:53:16 - Seeking Alpha
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Fusion Pharmaceuticals is an oncology company focused on precision medicine and radiopharmaceuticals. The company's clinical candidates show promise in targeting and treating cancers with unmet needs. Fusion has a strong financial position, with enough cash to fund operations until Q2 2025, and strategic partnerships to support its clinical pipeline.
2024-02-26 11:50:22 - Zacks Investment Research
Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect
Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.
2024-02-26 07:45:00 - PRNewsWire
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
HAMILTON, ON and BOSTON , Feb. 26, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences. TD Cowen 44th Annual Health Care Conference - The Company will participate in the "Prostate Cancer Corporate Panel Discussion" taking place on March 4, 2024, at 10:30 a.m.
2024-02-19 13:31:25 - InvestorPlace
7 Low-Cost Call Options With High-Profit Potential
Buying call options is a lot like (American) football. Sometimes, you run the ball up the middle.